ORLANDO, FL, USA (UroToday.com) - Cell cycle progression (CCP) is a validated genetic assay that assesses risk of individual prostate cancer progression and disease-specific mortality when combined with clinicopathologic parameters. PROCEDE-1000 is the largest prospective registry that was created to evaluate CCP test impact on personalizing prostate cancer treatment.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Untreated patients with newly diagnosed (< 6 months) localized prostate adenocarcinoma (n = 816) were enrolled. The physicians’ initial therapy recommendation (Pre-CCP) was recorded on the first questionnaire, based on biopsy data. Subsequently, CCP test was conducted on prostate biopsy tissue. Three post-CCP questionnaires recorded the physicians’ revised treatment recommendation, physician/patient treatment decision, and final treatment administered. Changes in treatments between the pre-CCP and post-CCP questionnaires were assessed to determine the impact of CCP testing.
Visual analog scale measurements indicated a significant increase in the physicians’ likelihood of recommending non-interventional treatment after CCP test. CCP score led to treatment change in 44% of patients, of whom 72% of changes were reductions in treatment. Reductions occurred across all treatment modalities—27% prostatectomy, radiation therapy (44% primary; 56% adjuvant), brachytherapy (46% interstitial; 66% HDR), and hormonal therapy (33% neoadjuvant; 68% concurrent). There was an increase in active surveillance from the initial interventional therapy. While 35.9% were recommended for conservative management pre-CCP, there was a 6.5% increase in non-interventional treatments during follow-up.
The group concluded that the CCP risk score has a significant impact in helping physicians and patients select a personalized treatment option.
Presented by Neal D. Shore, Judd Boczko, Naveen Kella, Brian Joseph Moran, E. David Crawford, Stephanie A. Hamilton, Rajesh R. Kaldate, Kirstin M Roundy, Michael K. Brawer, and Mark L. Gonzalgo at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA
Carolina Urologic Research Center, Myrtle Beach, SC; WESTMED Medical Group, White Plains, NY; The Urology and Prostate Institute, San Antonio, TX; Prostate Cancer Foundation of Chicago, Westmont, IL; University of Colorado Health Science Center, Aurora, CO; Myriad Genetic Laboratories, Inc., Salt Lake City, UT; University of Miami Miller School of Medicine, Miami, FL
Reported by Mohammed Haseebuddin, MD, medical writer for UroToday.com